Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

IQVIA Holdings, Inc. Common Stock (NY:IQV)

188.02 -3.13 (-1.64%)
Official Closing Price Updated: 4:10 PM EDT, Aug 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about IQVIA Holdings, Inc. Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Investor Optimism Declines Slightly As Dow Drops 250 Points
The CNN Money Fear and Greed index showed some decline in the overall sentiment among US investors. US stocks closed lower on Thursday as investors assessed recent batch of corporate earnings. 
Via Benzinga
IQVIA Named to FORTUNE’s 2023 List of “World’s Most Admired Companies,” Ranked #1 in Its Category for the Second Consecutive Year
From IQVIA
Via Business Wire
Earnings Outlook For IQVIA Holdings
 
Via Benzinga
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
These companies are changing their industries. 
Via The Motley Fool
IQVIA in Collaboration with Alibaba Cloud to Deliver Commercial & Clinical Solutions in China
From IQVIA
Via Business Wire
Will Investors Notice Exciting Sign On IQVIA Hldgs's Chart?
 
Via Benzinga
Analyst Ratings for IQVIA Hldgs
 
Via Benzinga
Expert Ratings for IQVIA Hldgs
 
Via Benzinga
IQVIA to Announce Fourth-Quarter and Full-Year 2022 Results on February 10, 2023
From IQVIA
Via Business Wire
Global Market for Medicines to Rise to $1.9 Trillion by 2027, says Report from IQVIA Institute
From IQVIA
Via Business Wire
World Wrestling Entertainment To Rally Around 12%? Here Are 10 Other Analyst Forecasts For Tuesday
Goldman Sachs boosted the price target for The Wendy's Company (NASDAQ: WEN) from $22 to $25. Goldman Sachs analyst Jared Garber maintained a Neutral rating on the stock. Wendy's shares fell 1.4% to... 
Via Benzinga
Where IQVIA Hldgs Stands With Analysts
 
Via Benzinga
Analyst Ratings for IQVIA Hldgs
 
Via Benzinga
8 Analysts Have This to Say About IQVIA Hldgs
IQVIA Hldgs (NYSE:IQV) has observed the following analyst ratings within the last quarter: 
Via Benzinga
7 Analysts Have This to Say About IQVIA Hldgs
Analysts have provided the following ratings for IQVIA Hldgs (NYSE:IQV) within the last quarter: 
Via Benzinga
2 Unstoppable Growth Stocks to Buy in 2023 and Beyond
These healthcare companies' revenue and earnings have grown, and they expect more growth. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022
 
Via Benzinga
Veracyte Stock Showing Market Leadership; Earns 93 RS Rating
Veracyte shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
Upgrades 
Via Benzinga
Target To Rally 29%? Plus This Analyst Predicts $245 For IQVIA Holdings
Piper Sandler boosted the price target on Target Corporation (NYSE: TGT) from $190 to $200. Target shares fell 13.1% to close at $155.47 on Wednesday. 
Via Benzinga
IQVIA and Clalit Health Services partner to advance research by launching the first Prime Site in Israel
From IQVIA
Via Business Wire
General Electric To Rally Around 14%? Here Are 5 Other Price Target Changes For Thursday
  Morgan Stanley raised General Electric Company (NYSE: GE) price target from $85 to $88. Morgan Stanley analyst Joshua Pokrzywinski maintained the stock with an Overweight rating. GE shares rose 2.2%... 
Via Benzinga
IQVIA: Q3 Earnings Insights
IQVIA Hldgs (NYSE:IQV) reported its Q3 earnings results on Wednesday, October 26, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings IQVIA Hldgs beat estimated... 
Via Benzinga
IQVIA Reports Third-Quarter 2022 Results
From IQVIA Holdings Inc.
Via Business Wire
Medpace Earnings Are 'Almost Unbelievable'; MEDP Stock Flies
Medpace earnings soared in Q3 as weakness in contract awards turned to strength, sending MEDP stock surging. 
Via Investor's Business Daily
Biosimilars Are Revolutionizing Healthcare: Is This Industry Leader a Buy?
Biosimilars are bringing down prescription drug costs without sacrificing quality. 
Via The Motley Fool
IQVIA CFO Ron Bruehlman to Speak at Credit Suisse Annual Healthcare Conference on November 8, 2022
From IQVIA Holdings Inc.
Via Business Wire
Q² Solutions Launches Innovative Self-Collection Safety Lab Panel in Collaboration With Tasso
From IQVIA
Via Business Wire
Tesla To $370? Plus HC Wainwright Slashes PT On This Stock By 67%
HC Wainwright & Co. cut KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) price target from $48 to $16. KalVista Pharmaceuticals shares fell 1.8% to $5.06 in pre-market trading. 
Via Benzinga
IQVIA to Announce Third-Quarter 2022 Results on October 26, 2022
From IQVIA Holdings Inc.
Via Business Wire
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.